Acadia regains rights to pimavanserin

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) regained rights to pimavanserin in the U.S. and Canada after it and Valeant Pharmaceuticals International Inc. (NYSE:VRX; TSX:VRX) jointly terminated a 2009 deal. Valeant gained rights to pimavanserin through its merger with Biovail Corp. this year, but decided that the program was not consistent with its strategic focus following the merger, according to Acadia. Acadia will receive $8.8 million in cash from Valeant. ...